Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

Study acronym: SPINOZA
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
Trial Details
NCT Number NCT07794670
Lead Sponsor NewAmsterdam Pharma
Conditions
(from sponsor)		 Preclinical Alzheimer's Disease
Related terms Alzheimer Disease
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov